Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer

Fotios Loupakis, Herbert I. Hurwitz, Leonard Saltz, Dirk Arnold, Axel Grothey, Quynh Lan Nguyen, Stuart Osborne, Jonathan Talbot, Stefanie Srock, Heinz Josef Lenz

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Background: Two first-line (1L) bevacizumab trials showed the prognostic value of primary tumour location in metastatic colorectal cancer (mCRC). In this retrospective subgroup analysis, further analysis of the predictive effect of bevacizumab is presented. Methods: Patients with sidedness information from two randomised phase III studies of bevacizumab + chemotherapy (CT) vs CT as 1L mCRC treatment were analysed retrospectively. Results: Sidedness was determined in 1590 (27% right and 73% left) of 2214 patients. Progression-free survival was improved with bevacizumab + CT vs CT in right-sided (HR = 0.75; 95% CI 0.61, 0.93; p = 0.008) and left-sided (HR = 0.76; 95% CI 0.67, 0.86; p < 0.001) mCRC (pooled analysis). Similarly, overall survival was numerically improved with bevacizumab + CT vs CT in right-sided mCRC (HR = 0.82; 95% CI 0.65, 1.03; p = 0.085), and significantly improved in left-sided mCRC (HR = 0.85; 95% CI 0.74, 0.98; p = 0.028). Conclusions: This analysis indicates that the effect of bevacizumab is independent of tumour location in mCRC.

Original languageEnglish (US)
Pages (from-to)1451-1455
Number of pages5
JournalBritish journal of cancer
Volume119
Issue number12
DOIs
StatePublished - Dec 11 2018

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this